Dow closes at record high on tame inflation report that also boosts small caps
U.S. PCE stands at 2.2% in Aug
Russell 2000 index up 1.5%
Bristol-Myers gains after schizophrenia drug approval
Costco slips after Q4 revenue misses estimates
Indexes: Dow up, S&P 500 down, Nasdaq down
Updates to 4:00 PM ET
By Echo Wang
Sept 27 (Reuters) -The blue-chip Dow Jones Industrial Average closed ata record high on Friday as investors welcomed a subdued inflation report that also lifted small-cap stocks which stand to benefit from moreinterest rates cuts by the Federal Reserve.
The technology-heavy Nasdaq slipped and the S&P 500 edged slightly lower but both indexes stayed close to recent record highs. All three Wall Street indexes logged their third consecutive week of gains.
“The market at this point..(is) pretty much pricing in a soft landing, and pricing in that we have defeated inflation, and that the Fed will be able to lower rates without causing a bunch of harm to the economy”, said Liz Young Thomas, head of investment strategy at SoFi in New York.
The Commerce Department reported a moderate rise in consumer spending while inflation pressures continued to ease. Separately, the University of Michigan's final September reading on consumer sentiment came in at 70.1, surpassing economists' expectations of 69.3, according to a Reuters poll.
According to preliminary data, the S&P 500 .SPX lost 7.64 points, or 0.13%, to end at 5,737.68 points, while the Nasdaq Composite .IXIC lost 73.41 points, or 0.40%, to 18,116.88. The Dow Jones Industrial Average .DJI rose 130.51 points, or 0.31%, to 42,305.62.
The Russell 2000 index .RUT, which tracks small caps that fare better in a low-rateenvironment, climbed to a one-week high.
Shares of NvidiaNVDA.O slipped, weighing on the technology-heavy Nasdaq.
Investors now slightly favor a 50-basis-point cut at the Fed's next meeting with a 52.1% chance, up from a coin toss before the data, as per the CME Group's FedWatch Tool.
Cooling price pressures prompted the Fed to cut rates by 50 bps last week. Focus will now shift to a slew of labor market reports due next week.
Among individual stocks, Bristol-Myers Squibb BMY.N surged after the U.S. FDA approved its schizophrenia drug.
Costco Wholesale COST.O dropped after posting downbeat fourth-quarter revenue.
U.S.-listed shares of Chinese firms, including AlibabaBABA.N, PDD Holdings PDD.O and NetEase NTES.O gained after China's central bank lowered interest rates and injected liquidity into the banking system.
The optimism extended to miners, with Arcadium ALTM.N gaining, and U.S.-listed shares of BHP BHP.N also advancing.
PCE, the shorter term view https://reut.rs/3WXgbkd
Reporting Echo Wang in New York; Additional Reporting by Johann M Cherian and Purvi Agarwal in Bengaluru; Editing by Anil D'Silva, Maju Samuel and David Gregorio
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
